Wall Street Analysts Believe Nektar (NKTR) Could Rally 64.53%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 64.5% in Nektar (NKTR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Does Nektar (NKTR) Have the Potential to Rally 62.75% as Wall Street Analysts Expect?
The consensus price target hints at a 62.8% upside potential for Nektar (NKTR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets
Nektar Therapeutics (NKTR) develops novel immunomodulatory drugs targeting autoimmune diseases and oncology, leveraging its expertise in immune system regulation. Recent Phase 2 results for Atopic Dermatitis met endpoints, validating NKTR's approach and boosting confidence in its platform's clinical potential. NKTR's pipeline includes rezpegaldesleukin for other indications, and NKTR-255 for cancer, addressing significant unmet medical needs.
Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout
Nektar Therapeutics has pivoted from oncology to focus on autoimmune and inflammatory diseases, with Rezpegaldesleukin (Rezpeg) as its lead asset. NKTR's value now centers on Treg biology, advancing Rezpeg and NKTR-0165, and leveraging legacy oncology partnerships for monetization. Key catalysts are upcoming Q1 2026 readouts: Phase 2b alopecia areata data and 36-week atopic dermatitis data for Rezpeg.
Nektar Therapeutics Q3 Loss Narrower Than Expected, Revenues Rise Y/Y
NKTR posts a narrower Q3 loss and a revenue beat, while its rezpeg program advances with key phase IIb milestones.
Nektar Therapeutics (NKTR) Reports Q3 Loss, Beats Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $2.7 per share a year ago.
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Nektar (NKTR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts See a 50.01% Upside in Nektar (NKTR): Can the Stock Really Move This High?
The mean of analysts' price targets for Nektar (NKTR) points to a 50% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript
Nektar Therapeutics (NASDAQ:NKTR ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Howard W. Robin - CEO, President & Director Jonathan Zalevsky - Senior VP and Chief Research & Development Officer Korin Franklin - Corporate Participant Sandra A.
Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y
NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Nektar Therapeutics (NKTR) came out with a quarterly loss of $2.95 per share versus the Zacks Consensus Estimate of a loss of $3.13. This compares to a loss of $3.75 per share a year ago.
3 Bullish Biotech Stocks With Explosive Growth Trends
Investing in biotechnology stocks is similar to the drug development process itself. That is, investors frequently experience long periods of nothing much happening, interrupted by periods of sharp movement.
